Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with acute myocardial infarction (MI), according to a study published ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.

Total adverse events of heart failure or all-cause mortality were reduced with empagliflozin, regardless of kidney function. (HealthDay News) — Empagliflozin has kidney protective effects and ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

Finerenone may lower risks for kidney and cardiovascular events for adults with chronic kidney disease and type 2 diabetes, ...

THE Philippine Health Insurance Corp. (PhilHealth) said on Wednesday that member contribution rates will not rise because they are fixed by law, adding that it will seek to offset the loss of ...

Legionella pneumophila is a bacterium found in natural water sources and artificial water systems. The most widely reported manifestation of Legionella infection is pneumonia, which is also known as ...

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...

New data shows no increased cardiovascular risk of the osteoporosis drug vs anabolic agents — and even suggests a lower risk.